Posters
« Back
The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
EP28949
Poster Title: The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
Submitted on 14 Aug 2018
Author(s): SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2
Affiliations: 1The Jackson Laboratory, Bar Harbor, Maine USA; 2Indiana University School of Medicine, Indianapolis, Indiana USA
This poster was presented at AAIC 2018
Poster Views: 573
View poster »


Poster Information
Abstract: The preclinical testing core (PTC) of the Model Organism Development for Late Onset Alzheimer’s Disease (MODEL-AD) consortium has established a streamlined preclinical drug testing strategy with go/no-go decision points that allow critical and unbiased assessments of potential therapeutic agents. The goals of the PTC are to develop a testing strategy that maximizes the therapeutic potential of all drug candidates by initiating the dosing strategy prior to the onset of disease relevant biomarker readouts.
The PTC strategy includes a primary screen to determine: 1) drug formulation; 2) drug stability; and 3) in vivo pharmacokinetics and target tissue concentrations in models at disease-relevant ages. A secondary screen evaluates target engagement and disease modifying activity utilizing non-invasive PET/MRI as a pharmacodynamic (PD) readout matched to known disease pathology in the model. Compounds demonstrating positive PD effects in the secondary screen are further interrogated via a tertiary screen of functional assays that assess the compounds ability to normalize a disease-related phenotype in cognition and neurophysiological tests. For the present studies, we selected levetiracetam (LEV), a compound currently in clinical trials for the treatment of cognitive impairment associated with AD, for testing in 5XFAD mice.
Summary: The PTC pipeline for MODEL-AD using levetiracetam as a pipeline testing compound.Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3

Violating Gender Stereotypes
Lori Slivnik, Sabina Zakelj, Jasna Mikic, Aleksandra Kanjuo Mrcela, Jure Bon, Andraz Matkovic

Digiceuticals
Helana Lutfi and Shaban Nuredini

Clinical pattern in electrophysiological variants of acute acquired polyneuropathies and their clinical outcome, a three years data
Naseebullah, Salman Mansoor, Azhar Saeed